HHBT Stock Overview
Engages in health and green industries. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HH Biotechnology Holdings Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.0001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -99.90% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
HHBT | US Real Estate | US Market | |
---|---|---|---|
7D | 0% | 2.7% | -0.5% |
1Y | n/a | 20.4% | 24.3% |
Return vs Industry: Insufficient data to determine how HHBT performed against the US Real Estate industry.
Return vs Market: Insufficient data to determine how HHBT performed against the US Market.
Price Volatility
HHBT volatility | |
---|---|
HHBT Average Weekly Movement | n/a |
Real Estate Industry Average Movement | 7.7% |
Market Average Movement | 6.5% |
10% most volatile stocks in US Market | 18.8% |
10% least volatile stocks in US Market | 3.3% |
Stable Share Price: HHBT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HHBT's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Sheng Jiang | www.greatchinaholdings.com |
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016.
HH Biotechnology Holdings Company Fundamentals Summary
HHBT fundamental statistics | |
---|---|
Market cap | US$1.41k |
Earnings (TTM) | US$2.88m |
Revenue (TTM) | US$7.95m |
0.0x
P/E Ratio0.0x
P/S RatioIs HHBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HHBT income statement (TTM) | |
---|---|
Revenue | US$7.95m |
Cost of Revenue | US$5.18m |
Gross Profit | US$2.77m |
Other Expenses | -US$107.02k |
Earnings | US$2.88m |
Last Reported Earnings
Sep 30, 2016
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did HHBT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/28 18:28 |
End of Day Share Price | 2024/09/30 00:00 |
Earnings | 2016/09/30 |
Annual Earnings | 2015/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HH Biotechnology Holdings Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|